FeNO provides further information in distinguishing different phenotypes in asthma, allowing
a much more appropriate control of the disease, especially in patients with difficult/severe …

The present review is focused on literature concerning the relevance of fractional exhaled
nitric oxide (FeNO) in clinical practice from a pathophysiological point of view. There is …

Background Elevated exhaled nitric oxide fraction at a flow rate of 50 mL· s− 1 (F ENO 50) is
an important indicator of T-helper 2-driven airway inflammation and may aid clinicians in the …

It is not fully understood how the fraction of exhaled nitric oxide (FeNO) varies with age and
gender in healthy individuals. We aim to describe the evolution of FeNO with age, giving …

Background: Tobacco smoking affects both the fraction of exhaled nitric oxide (FeNO) and
blood eosinophil (B-Eos) count, two clinically useful biomarkers in respiratory disease that …

While several randomized control trials (RCTs) have evaluated the use of fractional exhaled
nitric oxide (FeNO) to improve asthma outcomes, none used FeNO cut‐offs adjusted for …

Background Current guidelines recommend tailoring of asthma management according to
disease control, which is largely defined by increased symptoms and deterioration in lung …

Background Bronchial provocation tests are standard for diagnosing the etiology of chronic
cough, but they are time consuming and can induce severe bronchospasm. A safer and …

Background Fractional exhaled nitric oxide (F eno) is used clinically as a biomarker of
eosinophilic airway inflammation. Awareness of the factors influencing F eno values is …

Individualisation of asthma treatment regimens on the basis of biomarkers is necessary to
improve asthma control. However, the suboptimal properties of currently available …